Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

@article{Regules2016FractionalTA,
  title={Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.},
  author={Jason A. Regules and Susan B Cicatelli and Jason W. Bennett and Kristopher M. Paolino and Patrick S Twomey and James E. Moon and April K Kathcart and Kevin D Hauns and Jack L Komisar and Aziz N Qabar and Silas A. Davidson and Sheetij Dutta and Matthew E. Griffith and Charles D Magee and Mariusz Wojnarski and Jeffrey R Livezey and Adrian T Kress and Paige E Waterman and Erik Jongert and Ulrike Wille-Reece and Wayne Volkmuth and Daniel E Emerling and William H Robinson and Marc J. J. Lievens and Danielle Morelle and Cynthia K. Lee and Bebi Yassin-Rajkumar and Richard Weltzin and Joe Cohen and Robert M. Paris and Norman C. Waters and Ashley J. Birkett and David C Kaslow and William Ripley Ballou and Christian F. Ockenhouse and Johan Vekemans},
  journal={The Journal of infectious diseases},
  year={2016},
  volume={214 5},
  pages={762-71}
}
BACKGROUND Three full doses of RTS,S/AS01 malaria vaccine provides partial protection against controlled human malaria parasite infection (CHMI) and natural exposure. Immunization regimens, including a delayed fractional third dose, were assessed for potential increased protection against malaria and immunologic responses. METHODS In a phase 2a, controlled, open-label, study of healthy malaria-naive adults, 16 subjects vaccinated with a 0-, 1-, and 2-month full-dose regimen (012M) and 30… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS